🧬 BioMed Pulse · 2026-11-14 02:01 UTC

BIOMED PULSE

Saturday, November 14, 2026 — Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus (BVD) Ebola outbreak in the Democratic Republic of the Congo has now crossed into Nigeria, making it the largest Ebola outbreak ever recorded and still expanding fast across six provinces. Mood: urgent on outbreak containment; cautiously optimistic on longevity science, where a landmark aging-trajectory tool and a major physical-activity research series point toward actionable, biology-grounded paths to longer healthspan.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO EBOLA — DRC, KENYA, NIGERIA (CRITICAL)

  • As of the most recent WHO Disease Outbreak News, the BVD outbreak has expanded geographically to include imported cases in both Kenya and Nigeria, beyond the DRC's sustained high-level transmission. [1]
  • The November 6 WHO update confirmed the DRC outbreak continues to expand, with some areas showing slight case declines but overall transmission remaining intense across multiple health zones. [2]
  • The outbreak has spread from its origin in Mongbwalu health zone, Ituri Province, to at least 61 health zones across six DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, plus a new foothold in Sud Ubangi Province. [3]
  • WHO previously characterized this as the largest Ebola outbreak ever reported in the DRC, expanding faster than any prior Ebola event. [4]
  • CDC has previously activated enhanced Ebola airport screening at Washington Dulles and Atlanta Hartsfield-Jackson in response to this outbreak. [5][6]

SHAMONDA VIRUS — FRANCE (NOVEL PATHOGEN ALERT)

  • On October 20, 2026, France's National IHR Focal Point notified WHO of the first documented human infection with Shamonda virus (SHAV), an orthobunyavirus. [7]
  • The case was an immunocompromised older man from eastern France with no recent travel history who developed severe neurological symptoms; WHO notified on November 2, 2026. [7]
  • Shamonda virus was previously known only as an animal (largely livestock) pathogen; this marks a significant species-barrier crossing warranting close surveillance. [7]

YELLOW FEVER — WHO AFRICAN REGION

  • Between January 1 and October 12, 2026, the WHO African Region recorded 67 confirmed cases including 18 deaths across nine countries: Burkina Faso, Cameroon, Central African Republic, and others in West Africa. [8]
  • Transmission activity continues following a surge in the Americas in 2025 that carried into 2026, where six countries reported 79 infections in the first five months of the year. [9]

MERS-CoV — SAUDI ARABIA

  • Between January 1 and October 5, 2026, Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases, including one death, spread across six locations including Riyadh, Al Jouf, Arar, Hafr Al-Batin, Tabuk, and one additional site. [10]
  • No signal of sustained human-to-human transmission was noted; camel-to-human exposure remains the primary route. [10]

PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA

  • On October 2, 2026, WHO was alerted via media reports to the death of an employee of the Irkutsk Antiplague Research Institute of Siberia and the Far East (APRI) in the Russian Federation, who died following hospitalization for severe pneumonia.
  • The etiology remains undetermined; WHO flagged the occupational setting — a biosafety research institute — as a factor warranting follow-up.

HANTAVIRUS (ANDES VIRUS) — M/V HONDIUS CRUISE SHIP, MULTI-LOCATIONS

  • The Andes hantavirus (ANDV) outbreak linked to the cruise ship M/V Hondius, first notified to WHO on May 2, 2026, was last updated in a WHO Disease Outbreak News on July 2, 2026, representing the fifth posting on this event.
  • Hantavirus pulmonary syndrome carries a high case-fatality ratio; the cruise-ship transmission setting represented an unusual epidemiological context for ANDV, which is normally associated with rodent exposure in South America.

NIPAH VIRUS — INDIA (KERALA)

  • On June 11, 2026, Kerala State Health Department confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode District; the adult male patient developed symptoms May 30 and was hospitalized June 10 with neurological presentation.
  • NiV in Kerala has precedent from prior outbreaks; WHO and Indian authorities activated contact tracing protocols.

🧬 LONGEVITY & AGING

CLINICALAGE: MODELING YOUR BIOLOGICAL AGE FROM HEALTH RECORDS

  • A new framework called ClinicalAge, validated in the UK, models individualized aging trajectories using longitudinal electronic health records, moving beyond the blunt tool of chronological age to predict health outcomes.
  • A companion study published alongside ClinicalAge in Lancet Digital Health introduces a novel aging biomarker that captures aging trajectories from EHR data, providing a scalable, clinic-ready aging clock.
  • These tools could allow clinicians to identify patients who are biologically older than their birth year suggests, enabling earlier, targeted interventions.

PHYSICAL ACTIVITY AS A LONGEVITY PILLAR — LANCET HEALTHY LONGEVITY SERIES

  • A multi-paper series in Lancet Healthy Longevity argues physical activity is among the most evidence-backed, scalable interventions for healthy aging in both high-income and low-to-middle-income countries.
  • One paper in the series documents that physical inactivity and excess sedentary behaviour independently accelerate biological aging in older adults, with the two risks acting additively rather than interchangeably.
  • Researchers from the series call for multilevel action — from urban planning to clinical prescriptions — arguing that existing exercise intervention evidence is robust enough to implement now rather than await further trials.

MUSCLE HEALTH AND PHYSICAL FUNCTION AS AGING CLOCKS

  • A Lancet Healthy Longevity commentary by Suetta argues that physical function and muscle health metrics — grip strength, gait speed, muscle mass — are more clinically meaningful aging clocks than birth year alone.
  • This positions sarcopenia screening as a de facto longevity diagnostic, not merely a geriatric niche concern.

STATIN DISCONTINUATION IN OLDER ADULTS AND FRAILTY

  • A large population-wide retrospective cohort study using the UK Clinical Practice Research Datalink examined statin discontinuation in patients 65 and older, finding that frailty status significantly modifies outcomes when statins are stopped.
  • A linked commentary in Lancet Healthy Longevity flags this as a warning: blanket deprescribing of statins in older adults without frailty assessment may inadvertently raise cardiovascular risk in healthier older patients while potentially being safe in frail individuals.

ANIMAL PROTEIN, COGNITION, AND THE FEMALE-MALE DEMENTIA GAP

  • A global ecological analysis published in Future Science OA found associations between national animal protein supply, trajectories of cognitive aging, and the well-documented female-to-male gap in dementia prevalence, though ecological design limits causal inference.
  • The finding adds nutritional supply as a potential structural variable in dementia epidemiology alongside hormonal and longevity-differential explanations.

AI AND BIOLOGICAL AGE ESTIMATION FROM FACE PHOTOGRAPHS

  • A model published in Lancet Digital Health called FAHR-Face (Foundation AI models for Health Recognition by Face) demonstrated that face photographs can be used to estimate biological age and health risk, validated by researchers including Gladyshev VN, a leading longevity scientist.
  • A separate Lancet Digital Health study showed AI-based cardiac MRI segmentation outperformed clinicians at left ventricular analysis for mortality prediction, another example of AI-derived aging signals embedded in routine clinical imaging.

💊 NEW CURES & APPROVALS

TOFACITINIB CITRATE (GENERIC) — APOTEX

  • Apotex received an original ANDA approval for tofacitinib citrate, a JAK inhibitor used for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; the approval expands generic access to this immunomodulatory drug class.

MULTIBIC — FRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

  • Fresenius Medical Care received an original NDA approval (NDA219457) for MULTIBIC, a dialysate solution for hemodialysis patients, potentially expanding renal replacement therapy options.

OXDERYS — AVYXA HOLDINGS

  • Avyxa Holdings received an original NDA approval (NDA221093) for OXDERYS, containing the active ingredient doxorubicin hydrochloride, a chemotherapy agent in a new formulation for oncology indications.

NDA221291 — BAYER HEALTHCARE

  • Bayer Healthcare received an original NDA approval (NDA221291); full active ingredient and indication details were not specified in the data beyond the original approval action.

KANJINTI (TRASTUZUMAB-ANNS) SUPPLEMENT — AMGEN INC

  • Amgen received a supplemental BLA approval for KANJINTI (trastuzumab-anns, BLA761073), a trastuzumab biosimilar used in HER2-positive breast and gastric cancers, extending its approved labeling.

POHERDY (PERTUZUMAB-DPZB) SUPPLEMENT — SHANGHAI HENLIUS BIOTECH

  • Shanghai Henlius Biotech received a supplemental BLA approval for POHERDY (pertuzumab-dpzb, BLA761450), a pertuzumab biosimilar used in HER2-positive breast cancer in combination regimens.

ANASTROZOLE SUPPLEMENT — TEVA PHARMACEUTICALS

  • Teva received a supplemental ANDA approval for anastrozole, a third-generation aromatase inhibitor used as adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer.

🧪 CLINICAL TRIALS

SALANERSEN (BIIB115) FOR SPINAL MUSCULAR ATROPHY — BIOGEN

  • A trial registered November 13, 2026 (NCT07444476) is studying salanersen (BIIB115), a Biogen investigational drug, in participants aged 15 to 60 with spinal muscular atrophy (SMA), including both treatment-naive patients and those previously on risdiplam.
  • SMA is caused by loss-of-function variants in the SMN1 gene; salanersen represents a next-generation approach targeting splicing or SMN pathway modulation in a broad adult-to-middle-age SMA population.

BLINATUMOMAB COMBINATIONS IN OLDER ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

  • Trial NCT02143414 (phase II) is studying blinatumomab combined with chemotherapy or with dasatinib plus prednisone in older patients with acute lymphoblastic leukemia, leveraging the bispecific T-cell engager mechanism to reduce reliance on intensive cytotoxic regimens in older adults.

ALL-ORAL TRIPLE COMBINATION FOR IDH1-MUTANT AML — IVOSIDENIB, SONROTOCLAX, CHIDAMIDE

  • A new multicenter exploratory trial (NCT07937124) registered November 13, 2026 is testing an all-oral regimen of ivosidenib (IDH1 inhibitor), sonrotoclax (BCL-2 inhibitor), and chidamide (HDAC inhibitor) in adults with newly diagnosed IDH1 R132-mutant acute myeloid leukemia, targeting approximately 30 participants.
  • The triple oral strategy aims to avoid induction chemotherapy toxicity in a population that skews older, with IDH1 mutations common in patients over 60.

FRAILTY INDEX FOR PREDICTING ICU NEED AFTER HIP FRACTURE IN OLDER ADULTS

  • A prospective observational single-center study (NCT07936279) registered November 13, 2026 is evaluating the Modified Frailty Index-5 (mFI-5) score as a predictor of ICU admission and 30-day mortality in patients aged 65 and older undergoing hip fracture surgery.
  • Hip fracture is a sentinel event in aging biology, strongly associated with accelerated functional decline; a validated frailty-based triage tool could reduce preventable ICU admissions.

CHATBOT-ASSISTED FLU VACCINATION UPTAKE IN ADULTS 65-PLUS

  • A partially blinded parallel-group RCT (NCT07934888) registered November 13, 2026 is testing a rule-based chatbot augmented with ChatGPT-supported real-time Q&A functions to promote seasonal influenza vaccination in community-dwelling people aged 65 and older.

DETERMINANTS OF PHYSICAL ACTIVITY IN POSTMENOPAUSAL WOMEN

  • An observational study (NCT07936916) registered November 13, 2026 is examining how hormonal and physiological changes at menopause — including shifts in body composition, physical performance, and self-esteem — drive or suppress physical activity behaviors in postmenopausal women.
  • This trial connects directly to the Lancet Healthy Longevity series finding that sedentary behavior in older women is a modifiable longevity risk.

📢 PUBLIC HEALTH

RABIES ACTIVITY RISING IN THE UNITED STATES

  • CDC issued a statement on September 10, 2026 flagging a sharp increase in animal rabies activity and associated human exposures across the country, urging clinicians and the public to heighten post-exposure prophylaxis awareness.

DRUG-RESISTANT BACTERIA SHARPLY RISING — CDC REPORT

  • A CDC report released September 23, 2026 found a dramatic increase in a dangerous type of drug-resistant bacteria in U.S. healthcare settings, compounding existing antimicrobial resistance concerns.

CONGENITAL SYPHILIS UP FOR 12TH CONSECUTIVE YEAR

  • CDC's latest STI surveillance data shows U.S. congenital syphilis cases increased for the 12th consecutive year in 2024, underscoring persistent failures in prenatal screening and treatment access.

LISTERIA OUTBREAK IN PREPARED MEALS — ONGOING

  • As of late October 2026, CDC continues to urge consumers to check refrigerators and freezers for recalled prepared meal products linked to an ongoing Listeria outbreak, noting that illnesses persisted despite multiple product recalls.

U.S. COMPLETES WHO WITHDRAWAL

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and what it characterized as politicization of the organization, with a stated shift toward bilateral health agreements.
  • This context is relevant to today's Bundibugyo outbreak: the U.S. is now responding to the DRC Ebola crisis outside the formal WHO coordination structure it previously anchored.

BIOMED PULSE is an informational briefing only and does not constitute medical advice. Sources: WHO Disease Outbreak News, CDC Newsroom, openFDA Drugs@FDA, ClinicalTrials.gov, Europe PMC / PubMed.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  5. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  6. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom
  7. Shamonda virus in human - France — WHO Disease Outbreak News
  8. Yellow fever - WHO African Region — WHO Disease Outbreak News
  9. Yellow fever - Global — WHO Disease Outbreak News
  10. Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261114-02-v136 · 2026-11-14 02:01 UTC · pulse.uzylab.com